Why is 2026 already a record year for M&A activity?

Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP makes the difference.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

14 September 2026 Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms.

Regulation & Industry

Built to be bought? What makes companies acquisition-ready

11 September 2026 For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.

Regulation & Industry

Patent lawyers and judges discuss lofty UPC issues in grand London venue

10 September 2026 UPC judges and practitioners from firms including Freshfields, Kather Augenstein, EIP, Simmons & Simmons and Brinkhof converged at CIPA’s annual conference to offer candid views on the court’s biggest pressure points, from overloaded German divisions to harmonisation and cross-court influence.

More features

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-partner team of IP and corporate lawyers from Pillsbury

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

Built to be bought? What makes companies acquisition-ready

Patent lawyers and judges discuss lofty UPC issues in grand London venue

J&J names two-decade veteran as chief IP counsel

Why is 2026 already a record year for M&A activity?

More on this story

Editor's picks

Editor's picks

More features